AdvanCell Isotopes ²¹²Pb Generator
Radiopharmaceutical Alpha Isotope Generator
The AdvanCell ²¹²Pb Generator is a world-first alpha isotope generator which addresses the greatest unmet need in targeted alpha therapy – the reliable & scalable supply of isotope. The manufacture of clinical doses of a high-value isotope Alpha 212® (Lead-212) for use in targeted radionuclides therapy is a gamechanger for prostate & several other cancer treatments. Due to Lead-212’s short half-life, transporting, storing & administering the isotope is time sensitive. Scalable local production of these rare alpha emitting isotopes & turning them into cancer therapies enables greater access to treatments for patients who need it most.
Date of Launch
2022
Development Time
more than 36 Month
Target Regions
North America, Asia, Australia / Oceania, Europe
Target Groups
Consumers / Users, Trade / Industry, Public Sector / Government